Trial results

$TARS — TP-04

Tarsus Pharmaceuticals, Inc. (TARS) TP-04: trial results in ocular rosacea, 2027.

Research by Catalyst Intel

The catalyst

"TP-04: The Phase 2 Kore trial for the potential treatment of ocular rosacea continues to progress, with topline data expected in the first half of 2027."

— Tarsus Pharmaceuticals, Inc., 8-K filed 2026-11-03 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

TARS-TP04-2026

Company

Tarsus Pharmaceuticals, Inc.

Kind

Trial results

Indication

ocular rosacea

Window

2027-01-01 – 2027-06-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.